Will Roche (RHHBY) Stock Be Helped By Santaris Pharma Acquisition?

NEW YORK (TheStreet) -- Roche Holding (RHHBY) said it will buy Santaris Pharma, a privately-held Danish biotech company, for up to $450 million in cash, according to Reuters.

Santaris develops drugs to fight liver cancer, head and neck cancer, and against metabolic and infectious diseases.

It is partly owned by Danish venture capital firm Sunstone, which earlier this year considered a U.S. listing for the company, Reuters said. 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Shares of Roche Holding are down -0.79% to $35.98.

RHHBY ChartRHHBY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

Roche Lifts Full-Year Outlook After Solid Q2 Earnings Beat

China Was Right to Walk Away From Failed U.S. Trade Talks

Roche Expands Into App-Based Digital Health With mySugr Deal